Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650973 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
A Phase 1 study of Healthy, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 4
- Study locations
NCT02650973 is a Phase 1 study of Healthy that has completed, run by Coherus Oncology. The registered enrollment target is 122 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02650973, a Phase 1 study of Healthy, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of CHS-1701 (Coherus pegfligrastim) or 6mg SC dose of Neulasta (pegfilgrastim) given during each period.
Conditions Studied
Interventions
- DRUG Pegfilgrastim
- DRUG CHS-1701
Study Locations (4)
California
- WCCT - Cypress
Ohio
- Medpace CPU - Cincinnati
Texas
- ICON - San Antonio
Wisconsin
- Spaulding - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02650973
The ClinicalTrials.gov registry entry for NCT02650973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower). The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Pegfilgrastim is the first listed.
NCT02650973 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT02650973 about?
NCT02650973 is a clinical study titled "Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta". This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of CHS-1701 (Coherus pegfligrastim) or 6mg SC dose of Neulasta (pegfilgrastim) given during each period.
What is the current status of trial NCT02650973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2016-02. Estimated completion is 2016-06.
What conditions does trial NCT02650973 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02650973?
The interventions under investigation include: Pegfilgrastim (DRUG), CHS-1701 (DRUG).
Who is sponsoring clinical trial NCT02650973?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02650973 being conducted?
This trial has 4 study locations across California, Ohio, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.